TAKARATAKARA BIO INC.

Corporate History

As of March 31, 2020

1925 Established Takara Shuzo Co., Ltd
1970 Launched the Central Research Laboratories in the city of Otsu, Shiga
Succeeded in the world's first large-scale production technology for Bunashimeji mushrooms
1979 Commenced sales of the first domestically produced restriction enzymes as reagents for genetic engineering research
Entered Biomedical Business
1988 Acquired exclusive distribution rights in Japan for a gene amplification system using PCR technology
1993 Obtained worldwide PCR-related patent licenses to manufacture PCR products
1993 Established Takara Biotechnology (Dalian) Co., Ltd. in China, in order to manufacture life science research reagents
1995 Established Takara Biomedical Europe S.A.(currently Takara Bio Europe S.A.S) in Paris, France, in order to sell life science research reagents
1995 Developed the RetroNectin® Method for highly-efficient retrovial transduction in hematopoietic stem cells
1995 Established Bohan Biomedical Inc.(currently Takara Korea Biomedical Inc.) in Seoul, Korea
1996 Obtained patent rights related to LA-PCR method
1996 Discovered Apoidan-U involved in Kelp induces apoptosis in cancer cells
Launched the sales of Apoidan-U (Fucoidan series)
2000 Established DRAGON GENOMICS Co., LTD. (merged to Takara Bio in 2002)
Launched full-scale genetic analysis services
2001 Established Mizuho Norin Co., Ltd. (transferred in 2019)
2002 Established Takara Bio Inc. in the city of Otsu, Shiga, split off from Takara Shuzo, Co., Ltd.
2002 Established Takara Bio Farming Center Inc. (transferred in 2019)
2004 Established Takara Biomedical Technology (Beijing) Co., Ltd. in China
2004 Listed on the TSE Mothers Index
2005 Acquired U.S.-based Clontech Laboratories, Inc. (currently Takara Bio USA, Inc.)
2007 Established KINOKO CENTER KIN INC. in Okinawa
2010 Started clinical trial of Oncolytic Virus C-REV
2011 Established DSS Takara Bio India Pvt. Ltd. in New Delhi, India
2014 Acquired Cellectis AB (currently Takara Bio Europe AB) in Göteborg, Sweden
2014 Launched the Center for Gene and Cell Processing
Started CDMO business providing manufacturing and development support services for regenerative medicine products, etc.
2015 Launched new research facility in Kusatsu, Shiga
Headquarters functions relocated
2016 Changed listing to the First Section of the TSE
2016 Executed exclusive license agreement relating to C-REV with Otsuka Pharmaceutical Co., Ltd.
2017 Submitted the IND application for Phase I/II clinical trial of CAR gene therapy in Japan
2017 Acquired Rubicon Genomics, Inc. by wholly-owned subsidiary Takara Bio USA Holdings, Inc., thereafter merged to Takara Bio USA, Inc.
2017 Submitted IND application for Phase II clinical trial of Oncolytic Virus C-REV in Japan
2017 Acquired Wafergen Bio-systems, Inc. by wholly-owned subsidiary Takara Bio USA Holdings, Inc., thereafter merged to Takara Bio USA, Inc.
2018 Designated NY-ESO-1 siTCRTM as a product under the "SAKIGAKE Designation System", thereafter succeeded to Otsuka Pharmaceutical Co., Ltd.
2018 Executed exclusive license agreement relating to NY-ESO-1 siTCRTM and CD19 CAR gene therapy products with Otsuka Pharmaceutical Co., Ltd.
2019 Transferred the AgriBio Business
2020 Launched the Center for Gene and Cell Processing II

return to top

Our website uses cookies to ensure that we give you the best user experience.Read more
By continuing to use our site, you consent to our cookies.

Accept